- KR₩6tn
- KR₩6tn
- KR₩2tn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 36.36 | ||
| PEG Ratio (f) | 1.54 | ||
| EPS Growth (f) | 30.82% | ||
| Dividend Yield (f) | 0.64% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.73 | ||
| Price to Tang. Book | 3.14 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.88 | ||
| EV to EBITDA | 25.04 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.41% | ||
| Return on Equity | 8.68% | ||
| Operating Margin | 8.42% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 1,687,810.32 | 1,775,846.94 | 1,858,983.76 | 2,067,791.45 | 2,186,637.59 | 2,364,013 | 2,631,333 | 6.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +22.68 | -0.94 | -8.42 | -9.86 | +45.64 | +17.88 | +49.3 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Yuhan Corp is a Korea-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical Business segment manufactures and sells non-prescription drugs, such as analgesics, anti-inflammatory drugs, probiotics, nutritional supplements, and wound-healing agents, as well as prescription drugs, including treatments for diabetes, hyperlipidemia, hypertension, hepatitis, acquired immunodeficiency syndrome (AIDS), bone marrow cancer, cough suppressants, and breast cancer. The Overseas Business segment engages in the export of AIDS treatment intermediates. The Healthcare Business segment provides household goods, such as bleach. Additionally, the Company sells licenses. The Company sells its products in both domestic and overseas markets.
Directors
- Jeong Hui Lee PRE (69)
- Wuk Je Cho CEO (66)
- Jong Hyeon Park VPR
- Jae Gyo Kim MDR (54)
- Sang Cheol Kim MDR (60)
- Byeong Man Lee MDR (62)
- Yeong Rae Lee MDR (60)
- Se Wung Oh MDR (50)
- Hyo Yeong Yim MDR (52)
- Dong Gyun Jung OTH (52)
- Ju Yeong Jung OTH (53)
- Dae Sik Kang OTH (49)
- Jae Hun Kim OTH (54)
- Jong Gyun Kim OTH (54)
- Seong Su Kim OTH (56)
- Eun Hui Park OTH (49)
- Nam Jin Park OTH (52)
- Yin Bo Shim OTH (51)
- Jeong Su Son OTH (51)
- Jae Geol Woo OTH (75)
- Jae Cheon Yoo OTH (53)
- Seok Beom Yoon OTH (73)
- Seong Gil Chi NID (58)
- Jun Cheol Kim NID (56)
- Cheol Lee NID (71)
- Dong Jin Park NID (56)
- Yeong Jae Shin NID (54)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- June 20th, 1926
- Public Since
- November 1st, 1962
- No. of Employees
- 1,594
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KSE- Shares in Issue
- 73,294,945
- Address
- 74, Noryangjin-ro, Dongjak-gu, SEOUL, 06927
- Web
- https://www.yuhan.co.kr
- Phone
- +82 28280181
- Auditors
- Samil PricewaterhouseCoopers
Upcoming Events for 000100
Q3 2026 Yuhan Corp Earnings Release
Similar to 000100
Aprogen Biologics
Korea Exchange - KSE
Bionote
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
FAQ
What is the Yuhan share price?
As of Today at 24:16 UTC, shares in Yuhan are trading at KR₩86,000. This share price information is delayed by 15 minutes.
How has the Yuhan share price performed this year?
Shares in Yuhan last closed at KR₩86,000 and the price had moved by -19.63% over the past 365 days. In terms of relative price strength the Yuhan share price has underperformed the FTSE Developed Asia Pacific Index by -55.16% over the past year.
What are the analyst and broker recommendations for Yuhan?
The overall consensus recommendation for Yuhan is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Yuhan dividend yield?
The Yuhan dividend yield is 0.7% based on the trailing twelve month period.
Does Yuhan pay a dividend?
Last year, Yuhan paid a total dividend of KR₩600, and it currently has a trailing dividend yield of 0.7%. We do not have any data on when Yuhan is to next pay dividends.
When does Yuhan next pay dividends?
We do not have data on when Yuhan is to next pay dividends. The historic dividend yield on Yuhan shares is currently 0.7%.
How do I buy Yuhan shares?
To buy shares in Yuhan you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Yuhan?
As of the previous close price of KR₩86,000, shares in Yuhan had a market capitalisation of KR₩6tn.
Where are Yuhan shares listed?
Here are the trading details for Yuhan:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 000100
What kind of share is Yuhan?
Based on an overall assessment of its quality, value and momentum Yuhan is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Yuhan share price forecast for 2026?
The analyst consensus target price for shares in Yuhan is KR₩129,538. That is 50.63% above the last closing price of KR₩86,000.
Analysts covering Yuhan currently have a consensus Earnings Per Share (EPS) forecast of KR₩1,998 for the next financial year.
Find out moreWhat is the trend in the Yuhan share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Yuhan. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -53.11%.
As of the last closing price of KR₩86,000, shares in Yuhan were trading -21.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Yuhan PE Ratio?
The Yuhan PE ratio based on its reported earnings over the past 12 months is 36.36. The shares last closed at KR₩86,000.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Yuhan?
Yuhan's management team is headed by:
- Jeong Hui Lee - PRE
- Wuk Je Cho - CEO
- Jong Hyeon Park - VPR
- Jae Gyo Kim - MDR
- Sang Cheol Kim - MDR
- Byeong Man Lee - MDR
- Yeong Rae Lee - MDR
- Se Wung Oh - MDR
- Hyo Yeong Yim - MDR
- Dong Gyun Jung - OTH
- Ju Yeong Jung - OTH
- Dae Sik Kang - OTH
- Jae Hun Kim - OTH
- Jong Gyun Kim - OTH
- Seong Su Kim - OTH
- Eun Hui Park - OTH
- Nam Jin Park - OTH
- Yin Bo Shim - OTH
- Jeong Su Son - OTH
- Jae Geol Woo - OTH
- Jae Cheon Yoo - OTH
- Seok Beom Yoon - OTH
- Seong Gil Chi - NID
- Jun Cheol Kim - NID
- Cheol Lee - NID
- Dong Jin Park - NID
- Yeong Jae Shin - NID